Mr. Dvorak exited Zimmer Biomet in 2017 after 10 years as CEO. He spent 16 years total with the company. During his tenure, he grew revenues from $3.5 billion to $7.7 billion, spearheaded several acquisitions and launched Zimmer Biomet into the robot-assisted surgery market.
“Think’s industry-leading active robot technology provides an unparalleled opportunity to democratize robotic technology in orthopedics,” Mr. Dvorak said in the release. “The technology will deliver precision and implant flexibility to healthcare customers while at the same time enabling future, clinically relevant innovations for industry partners.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
